KW vs GLUE Comparison

Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).